Hypertension Uncontrolled by Medication: Renal Denervation Emerges as an Alternative

이미지
Professor Choi Seung-hyuk said, “Renal denervation is a new treatment option that can be used for patients with resistant hypertension.” /Photo = Kim Jia, guest reporter for Health Chosun
According to the Korean Society of Hypertension, the number of people with hypertension in South Korea is estimated at approximately 13 million. The treatment environment for hypertension has continued to advance, enabling a considerable number of patients to manage their blood pressure appropriately, but about 38% of patients still have difficulty controlling their blood pressure. Some patients are unable to sufficiently control their blood pressure even after taking three or more antihypertensive medications, including diuretics. This is resistant hypertension.

Resistant hypertension carries a significant treatment burden because blood pressure cannot be lowered to the target level despite taking multiple medications. The psychological burden associated with taking more medications and concerns about drug side effects may increase. Poor blood pressure control also exposes patients to the risk of major complications, including stroke, myocardial infarction and peripheral vascular disease. This is why new treatment options are needed for patients with resistant hypertension. Choi Seung-hyuk, a professor of cardiology at Samsung Seoul Hospital, said, “For patients whose blood pressure is difficult to lower sufficiently with medication alone, treatment methods that can supplement drug therapy are needed.”

◇Lowering sympathetic nerve activity around the renal arteries to control blood pressure
Renal denervation, RDN, is considered the only alternative available for patients with resistant hypertension. The procedure lowers the activity of the sympathetic nerves involved in blood pressure regulation around the renal arteries. A catheter is inserted along the renal artery, after which energy is delivered to the vessel wall to reduce the activity of the surrounding nerves. The procedure is performed by inserting a thin catheter through a blood vessel near the groin to the renal artery, and it can generally be completed within an hour, including preparation. The effects of renal denervation have been confirmed in multiple clinical trials.

In the SPYRAL OFF MED study involving patients who were not taking antihypertensive medications, office systolic blood pressure decreased by an average of 9.2 mmHg and 24-hour ambulatory systolic blood pressure decreased by an average of 4.7 mmHg three months after the procedure. The reduction was observed in nighttime blood pressure as well as daytime blood pressure. In the SPYRAL ON MED study involving patients taking up to three antihypertensive medications, office systolic blood pressure decreased by an average of 9.9 mmHg six months after the procedure. This was similar to the reduction in blood pressure expected from adding one type of antihypertensive medication.

Long-term effects have also been confirmed. According to the Global SYMPLICITY Registry DEFINE study, the reduction in blood pressure continued for up to three years after the procedure. An integrated analysis of 2,137 participants in four SPYRAL clinical trials also showed that the clinical benefits continued through 36 months after the procedure. Professor Choi Seung-hyuk said, “Long-term follow-up data through five and 10 years are now available, and the effects have been confirmed to persist over those periods,” adding, “Some studies have also presented results from even longer periods of observation.”

이미지
Renal denervation is a procedure that helps control blood pressure by inserting a catheter along a blood vessel to the renal artery and then lowering sympathetic nerve activity around the renal artery. /Photo = Health Chosun DB
◇Overseas coverage has moved beyond treatment, while South Korea has yet to provide insurance coverage
Overseas, renal denervation is being used in actual patient treatment, and institutional access to the procedure is also expanding. In the United States, Medicare coverage has been provided to patients with uncontrolled hypertension since October 2025. Japan and France also began applying national health insurance coverage in 2026. Germany and Italy likewise operate insurance coverage systems through bundled payments.

Although the feasibility of applying the procedure to patients in South Korea has been confirmed domestically, patients still find it difficult to choose it as an actual treatment option. Professor Choi Seung-hyuk said, “Compared with overseas, where renal denervation is being actively used, the situation in South Korea is disappointing,” adding, “An environment needs to be established in which patients can receive the benefits of treatment at an appropriate time.”

The social and economic burden caused by hypertension in South Korea is considerable. Annual medical expenses for hypertension in South Korea amount to 4.5 trillion won, the largest figure among individual diseases. Total medical expenses for diseases of the circulatory system, which are closely associated with hypertension, amount to approximately 14 trillion won. Professor Choi Seung-hyuk said, “If hypertension is not properly controlled over an extended period, it can lead not only to health problems for individual patients but also to a social and economic burden as hospitalizations and long-term treatment increase due to complications.” He continued, “Renal denervation is not a treatment that replaces existing antihypertensive medications, but rather a method that supplements drug therapy. It can become an important option for patients who previously had no appropriate treatment options beyond lifestyle improvements and medication,” adding, “I hope that, based on sufficient discussion, patients who need renal denervation will be able to receive the benefits of treatment at an appropriate time.”

This article has been translated AI.

Editor’s Pick

You May Like